The introduction of DOACs has been a significant advancement in the management of thromboembolic disorders. They offer a more convenient and safer alternative to traditional anticoagulants, leading to better patient adherence and outcomes. This is particularly important in the context of an aging population, where the incidence of conditions like atrial fibrillation and venous thromboembolism is increasing.
